Big Pharma
29 July 2025 Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”.
28 July 2025
24 July 2025
22 July 2025
22 July 2025
18 July 2025
Latest Features
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
More News
17 July 2025 Pharma giant can’t stop generics from unveiling copies of flagship product | Lord Justice Arnold upholds UK findings of lack of inventive step and insufficiency.
16 July 2025 Pharma giant wins preliminary injunction ‘in public interest’ regarding a generic of its Selenious Acid Injection | Judge finds infringement by pharma company Eugia of two Orange Book patents.
15 July 2025 After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.
15 July 2025 Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan.
14 July 2025 This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of increased transparency requirements in clinical trials and their effects on the global patent system. The session focuses on recent regulatory changes, especially in Europe, and the challenges they present for IP protection.
10 July 2025 Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.
10 July 2025 The new partner brings more than 30 years’ experience, including in counselling pharmaceutical, life sciences, and medical device companies.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox